Mana Capital Acquisition (MAAQ) Competitors $0.52 +0.06 (+13.69%) As of 04/24/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsTrendsBuy This Stock MAAQ vs. SYBX, MRKR, LSB, MBRX, PRPH, QNTM, AFMD, TXMD, GOVX, and BGXXShould you be buying Mana Capital Acquisition stock or one of its competitors? The main competitors of Mana Capital Acquisition include Synlogic (SYBX), Marker Therapeutics (MRKR), Lakeshore Biopharma (LSB), Moleculin Biotech (MBRX), ProPhase Labs (PRPH), Quantum Biopharma (QNTM), Affimed (AFMD), TherapeuticsMD (TXMD), GeoVax Labs (GOVX), and Bright Green (BGXX). These companies are all part of the "pharmaceutical products" industry. Mana Capital Acquisition vs. Synlogic Marker Therapeutics Lakeshore Biopharma Moleculin Biotech ProPhase Labs Quantum Biopharma Affimed TherapeuticsMD GeoVax Labs Bright Green Synlogic (NASDAQ:SYBX) and Mana Capital Acquisition (NASDAQ:MAAQ) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, community ranking, profitability, risk and dividends. Is SYBX or MAAQ more profitable? Mana Capital Acquisition's return on equity of 0.00% beat Synlogic's return on equity.Company Net Margins Return on Equity Return on Assets SynlogicN/A -207.84% -114.81% Mana Capital Acquisition N/A N/A N/A Do insiders and institutionals have more ownership in SYBX or MAAQ? 63.4% of Synlogic shares are held by institutional investors. Comparatively, 68.4% of Mana Capital Acquisition shares are held by institutional investors. 3.0% of Synlogic shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has stronger valuation and earnings, SYBX or MAAQ? Mana Capital Acquisition has lower revenue, but higher earnings than Synlogic. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSynlogic$8K1,666.68-$57.28M-$2.51-0.45Mana Capital AcquisitionN/AN/AN/AN/AN/A Does the MarketBeat Community favor SYBX or MAAQ? Synlogic received 330 more outperform votes than Mana Capital Acquisition when rated by MarketBeat users. However, 100.00% of users gave Mana Capital Acquisition an outperform vote while only 69.54% of users gave Synlogic an outperform vote. CompanyUnderperformOutperformSynlogicOutperform Votes33169.54% Underperform Votes14530.46% Mana Capital AcquisitionOutperform Votes1100.00% Underperform VotesNo Votes Does the media favor SYBX or MAAQ? In the previous week, Synlogic had 1 more articles in the media than Mana Capital Acquisition. MarketBeat recorded 1 mentions for Synlogic and 0 mentions for Mana Capital Acquisition. Synlogic's average media sentiment score of 0.00 equaled Mana Capital Acquisition'saverage media sentiment score. Company Overall Sentiment Synlogic Neutral Mana Capital Acquisition Neutral SummarySynlogic and Mana Capital Acquisition tied by winning 4 of the 8 factors compared between the two stocks. Get Mana Capital Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for MAAQ and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MAAQ vs. The Competition Export to ExcelMetricMana Capital AcquisitionIn Vitro, In Vivo Diagnostic Substances IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$4.22M$4.22M$2.02B$7.81BDividend YieldN/AN/A2.75%4.30%P/E RatioN/AN/A22.1718.36Price / SalesN/AN/A56.21101.37Price / CashN/AN/A51.7234.62Price / BookN/AN/A1.984.18Net IncomeN/AN/A-$333.48M$247.71M7 Day Performance33.34%33.34%2.52%6.45%1 Month Performance15.53%15.53%-3.49%-3.14%1 Year Performance-30.68%-30.68%6.07%5.40% Mana Capital Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MAAQMana Capital AcquisitionN/A$0.52+13.7%N/A-39.1%$4.22MN/A0.001Gap UpHigh Trading VolumeSYBXSynlogicN/A$1.06+5.0%N/A-38.3%$12.40M$8,000.00-0.2580Gap DownMRKRMarker Therapeutics3.2717 of 5 stars$1.15+6.5%$13.17+1,044.9%-71.1%$12.32M$6.59M-0.9660LSBLakeshore Biopharma0.2578 of 5 stars$1.32-12.1%N/AN/A$12.28M$672.27M0.00773Gap UpMBRXMoleculin Biotech2.206 of 5 stars$0.87-4.8%$6.00+585.8%-74.5%$12.25MN/A0.0020PRPHProPhase Labs0.8779 of 5 stars$0.29+3.4%N/A-93.4%$12.15M$6.77M-0.23130QNTMQuantum BiopharmaN/A$6.30+1.0%N/AN/A$12.09MN/A-0.41N/AGap DownAFMDAffimed3.8043 of 5 stars$0.73+1.0%$13.50+1,740.5%-81.8%$11.81M$877,000.000.00200Analyst ForecastTXMDTherapeuticsMD0.5671 of 5 stars$1.01+2.0%N/A-40.6%$11.69M$1.76M0.00420Analyst ForecastGap UpGOVXGeoVax Labs2.4651 of 5 stars$0.83-8.1%$12.90+1,455.2%-35.1%$11.48M$3.95M-0.1510News CoverageGap UpBGXXBright GreenN/AN/AN/AN/A$11.47MN/A-1.002Gap Down Related Companies and Tools Related Companies SYBX Alternatives MRKR Alternatives LSB Alternatives MBRX Alternatives PRPH Alternatives QNTM Alternatives AFMD Alternatives TXMD Alternatives GOVX Alternatives BGXX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MAAQ) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump purposefully forcing markets to crash…Whether you agree with the plan or not doesn’t matter. It’s happening. The only question is – are you re...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mana Capital Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mana Capital Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
